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Abstract
While cancer patients often experience tumor reduction after receiving chemotherapy, tumors
can eventually emerge from a state of dormancy. Cancer cells treated with the topoisomerase II
poison, etoposide (ETO), enter senescence, which is a durable and prolonged cell cycle growth
arrest. Different murine lung cell lines were screened for their levels of senescence induction by
ETO, and those showed promising senescence induction were then treated with the senolytic,
ABT263, to promote apoptosis. The hypothesis of this work was that non-small cell lung cancer
cell lines will have different degrees of senescence and that the magnitude of the response to
senolytics would reflect the extent of senescence induction. An additional goal of this study was
to identify an appropriate mouse lung cancer line that could be used to study the interactions with
the immune system. X577, E889, X381 and CMT167 cells had different degrees of senescence,
and had different degrees of response to the treatment with ABT263. However, there was no
clear correlation between the extent of senescence induction and the response to ABT263, and
this is assumed to be due to the different genetic makeup of the cells. After analysis of the time
to recovery from the treatment with ETO and ABT263, it was determined that X577 cells had
the potential be investigated in vivo.
1. Introduction
1.1. Cancer background
Cancer is a disease in which cells undergo mutations that allow them to grow uncontrollably and,
in some cases, to metastasize. Cancer is thought to be driven by defects in the host’s genes or by
defects in gene regulation. Cancer cells differ from normal cells in their ability to sustain
proliferative signaling, evade growth suppressors, resist cell death, enable replicative
immortality, induce angiogenesis, and activate invasion and metastasis (Hanahan, 2011).
According to the NIH, lung cancer is one of the leading causes of new cancer cases in 2021. It
was estimated that lung cancer would represent 12.4% of all new cancer cases in the U.S., and,
compared to other cancer related deaths, there were going to be 22% lung cancer deaths with the
five-year survival rate of 21.7% (NIH, 2021).
1.2. Lung cancer background
There are two main types of lung cancer, non-small cell lung cancer (NSCLC) and small cell
lung cancer (SCLC). The main subtypes of NSCLC are adenocarcinoma, squamous cell
carcinoma, and large cell carcinoma. About 80-85% of lung cancers are NSCLC.
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Adenocarcinomas start in cells that normally secrete mucus and they’re usually found in the
outer parts of the lung and are more likely to be found before they have spread. This cancer
occurs mainly in people that smoke or used to smoke; it is also the most common type of lung
cancer seen in people who don’t smoke. It is more common in women than in men, and it is
more likely to occur in younger people than other types of lung cancer.
Squamous cell carcinomas start in squamous cells, which are flat cells that line the inside of the
airways in the lungs and it can be found in the central part of the lungs, near a main airway
(bronchus).
Large cell (undifferentiated) carcinomas can appear in any part of the lung, this type of lung
cancer tend to grow and spread quickly, which can make it harder to treat.
SCLC tends to grow and spread faster than NSCLC and about 70% of patients with SCLC will
have cancer that has already metastasized by the time they are diagnosed. There are two main
types of small cell lung cancer, small cell carcinoma and combined small cell carcinoma.
Chemotherapy and radiation therapy work best at treating SCLC because of how fast it grows.
Unfortunately, for most people, the cancer will return at some point.
There are different treatments for NSCLC, some of which are, but not limited to, surgery,
radiation therapy, chemotherapy, targeted therapy, immunotherapy, laser therapy, photodynamic
therapy, cryosurgery, and electrocautery. Small cell lung cancer has six types of standard
treatments: surgery, chemotherapy, radiation therapy, immunotherapy, laser therapy, and
endoscopic stent placement.
1.3. Chemotherapy treatment
Chemotherapy uses drugs to stop the growth of cancer cells, either by killing the cells or by
stopping the cells from dividing. Chemotherapy can be used to cure cancer, lessen the chance it
will return, or stop or slows its growth. It can be used to shrink tumors in patients that experience
pain and other problems from cancer. Systemic chemotherapy is chemotherapy that is taken
orally, injected intravenously or intramuscularly. Regional chemotherapy is chemotherapy
placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen.
Chemotherapy drugs can be used alone or in combination with other chemotherapy drugs or
immunotherapy. Chemotherapy is used with other cancer treatments to decrease the size of
tumor before surgery, kill cancer cells that may remain after surgery or radiation therapy, kill
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cancer cells that have returned or metastasized to other parts in the body, or help other
chemotherapy drugs work better.
According to the American Cancer Society, chemotherapeutic drugs can cause side effects, the
magnitude of which depend on the type and dose of drugs given and how long they are taken.
Some side effects examples are, but not limited to, hair loss, mouth sores, loss of appetite or
weight changes, nausea and vomiting, and diarrhea or constipation. Chemotherapeutic drugs can
also affect the bone marrow blood-forming cells and can lead to increased chance of infections,
easy bruising or bleeding, and fatigue. These side effects usually subside after treatment is
finished. Although patients can be given drugs that can help prevent or reduce nausea and
vomiting (American, 2020), there are no available treatment for other serious side effects such as
peripheral neuropathy, chemo-brain, renal damage from platinum based drugs, and cardiotoxicity
of drugs such as doxorubicin.
A two-step treatment of chemotherapy can slow down the growth of cancer and drive the tumors
to cell death giving the patient a longer remission period or suppressing cancer recurrence. The
two-step approach we have been studying is the induction of senescence followed by the use of
senolytics.
1.4. Senescence
Senescence is a durable and prolonged growth arrest by which cancer cells can escape
chemotherapy-induced death (Sharpless et. al., 2015). Senolytics are a drug class that targets and
kills senescent cells (Dorr et. al., Xu et. al., Zhu et. al., 2013). Senescence induction by different
stimuli share some common characteristics including an essentially stable growth arrest, relative
resistance to apoptosis, persistent DNA damage signaling, changes in heterochromatin,
decreased lamin B1 levels, and increased expression of the cyclin-dependent kinase inhibitors,
p16, p21 and senescence-associated β-galactosidase (SA-β-gal). Senescent cells secrete
proinflammatory cytokines, chemokines, matrix metalloproteinases bioactive lipids, noncoding
nucleotides, vesicles, and growth factors, collectively
termed the senescence-associated secretory phenotype
(SASP) (Prasanna et. al., 2021).
Senescence induction can also occur in tumor cells by
targeted chemotherapy. Figure on the right illustrates the
phenotype of senescent cells appears as macro-molecular
6

damage, dysregulated metabolism, apoptosis resistance, and a secretome which has diverse
inflammatory mediators, growth factors, and different enzymes called the senescence-associated
secretory phenotype (SASP) (Hernandez-Segura et. al., 2018).
There are different types of senescence: DNA damage-induced senescence, oncogene-induced
senescence, oxidative stress-induced senescence, chemotherapy-induced senescence,
mitochondrial dysfunction-associated senescence, epigenetically induced senescence, paracrine
senescence, and replicative senescence (Hernandez-Segura et. al., 2018).
DNA damage-induced senescence occurs when DNA is damaged and this damage can induce
either senescence or apoptosis, depending on how damaged the DNA is (Hernandez-Segura et.
al., 2018; Munoz-Espin, 2014). Oncogene-induced senescence occurs by the activation of
oncogenes, such as Ras, or the inactivation of tumor suppressors, such as PTEN (HernandezSegura et. al., 2018; Munoz-Espin, 2014; Sharpless et. al., 2015). Chemotherapy-induced
senescence occurs after the use of multiple anticancer drugs, such as the topoisomerase II poison,
ETO, which induce DNA damage, and others that can act through different mechanisms, such as
the inhibition of pro-survival proteins like the BCL2 family (Saleh et.al., 2020). Epigenetically
induced senescence occurs with the use of DNA methylase inhibitors, such as 5-asa-2’deoxycytudine, or histone deacetylases inhibitors, such as sodium butyrate (Petrova et. al., 2016).
Paracrine senescence is induced by the SASP produced by a primary senescent cell (Acosta et.
al., 2013). Replicative senescence occurs when there is a decrease in proliferation potential after
multiple cell division that eventually lead to total arrest (Hernandez-Segura et. al., 2018), which
is the shorting of telomeres as a consequence of multiple cell divisions in non-transformed cells
(Sharpless et. al., 2015).
ETO was the first agent recognized as a topoisomerase II (topo II) inhibiting anticancer drug. In
1983, the FDA approved ETO as a cancer treatment in clinical settings (Hande, 1998). ETO, is
converted to O-demethylated metabolites, in a reaction that is mediated by CYP3A4 and
CYP3A5; the metabolites have similar potency at inhibiting topoisomerase II as the parent
compound. The parent drug, ETO, and its metabolites stabilize the double-stranded DNA
cleavage normally catalyzed by topoisomerase II (topo II) and inhibit the religation of DNA
breaks. These double-strand DNA breaks subsequently trigger the desired antitumor effects
which is cell death, but can also be senescence (Yang, et. al., 2009).
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Induction of cellular senescence is a mechanism by which cancer therapies exert antitumor
activity and tumor stasis. Conversely, there is an increasing amount of evidence from preclinical
studies shows that radiation and chemotherapy cause accumulation of senescent cells both in
tumor and normal tissue. This increase of senescent cells in tumors can promote tumor relapse,
metastasis, and resistance to therapy; furthermore, senescent cells in normal tissue can contribute
to certain radiation- and chemotherapy-induced side effects (Prasanna et. al. 2021).
After senescence induction, cells can recover from senescence, and re-emerge into an actively
proliferating state (Chakradeo et. al., 2016; Saleh et. al., 2020). Although, the recovery process is
unclear, we believe that it can be from previously senescent cells, cells in growth arrest from
quiescent, or cells that are resistant to treatment. The senescent cells are in growth arrest;
however, a portion of the cell population may die. When the cells that have entered into
senescence are treated with a senolytic, a portion of the senescent cell population are targeted for
cellular death; this would leave some cells, those that did not enter senescence and those that
could resist the senolytic treatment, alive. The surviving cells will eventually grow and
proliferate as previously and even more aggressively than before because those cells are
considered to be drug resistant. This recovery phenomenon is seen in patients with cancer; they
are treated with chemotherapy and the treatment works for a period of time, which can be
months or years, and suddenly the cancer reoccurs more rigorous and aggressive than before.
This indicates that the use of senolytics is vital in regards to the clearance of the senescent cells.
1.5. Apoptosis
Apoptosis is a programmed cell death pathway that is associated with a set of biochemical and
physical changes involving the nucleus, the cytoplasm, and the plasma membrane. During the
early stages of apoptosis, the cells round up and shrink. In the cytoplasm, the endoplasmic
reticulum dilates and the cisternae swell to form vesicles and vacuoles. In the nucleus, chromatic
condenses and accumulate into dense compact masses and is fragmented internucleosomally by
endonucleases. The nucleus becomes convoluted and buds off into several fragments, which are
encapsulated within the forming apoptotic bodies. In the plasma membrane, cell junctions are
disintegrated and the plasma membrane becomes gets twisted around and eventually starts to
make a rounded outgrowth on the surface of the cell. The cell can then break up in an elaborate
manner which will lead to the falling away of several membrane spheres containing the packaged
cellular contents; this is identified as apoptotic bodies of various sizes (Lawen, 2003).
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1.6. Senolytics
Senescent cells express prosurvival proteins that block apoptosis, such as BCL 2 and BCLXL
(Chang et. al., 2016; Short et. al., 2019; Wang et. al., 2017). Senotherapeutics are a new drug
class that selectively kill senescent cells, which are known as senolytics (Saleh et. al., 2020;
Short et. al., 2019). During the last decade, several senolytics have been identified and have been
used in clinical trials. Preclinical data implies that senolytics alleviate disease in numerous
organs, improve physical function and resilience, and suppress all causes of mortality (Robbins,
et. al., 2020). Different senolytics were investigated for this study. ABT263, navitoclax,
ABT199, and A1155463 are BH3 mimetics which prevent the BCL2 family proteins from
inhibiting the action of pro-apoptotic proteins. Upon activation, the pro-apoptotic proteins
permeate the mitochondria, allowing cytochrome C release into the cytoplasm where it binds and
activate the apoptotic protease activating factor-1 allowing its binding to ATP and the formation
of the apoptosome resulting in the activation of caspase-3 and finally cellular apoptosis (Zhan et.
al., 2019). Another senolytic is ARV525, which is a BET family protein degrader, that is thought
to produce senolysis by targeting NHEJ and autophagy in senescent cells (Wakita, et. al., 2020).
1.7. Preliminary data and research introduction
The human lung cancer cell line, A549, was shown in our laboratory to undergo senescence upon
treatment with ETO, and to die upon exposure to the senolytic agent, ABT263, both in vitro and
in vivo (Saleh et. al.). However, these studies were performed in an immune deficient animal that
would not reject the human tumor cells. In order to identify a mouse cell line to study the
interaction of the immune system when treated with ETO and ABT263, mouse lung cancer cell
lines, including CMT167, with different genetic backgrounds (Noland et. al., 2011) were
investigated.
Senescence induction was monitored based on the upregulation of the lysosomal content, βgalactosidase expression, as well as the upregulation of Cathepsin D1, p21, p53, and the down
regulation of Lamin B1. Cells that responded to ETO by undergoing senescence were then tested
with senolytics, including ABT263, and ARV825.
ABT263 is a senolytic which targets the BCL2 family (Zhan et. al., 2019). ABT263 has shown to
be toxic when used in large doses (Zhan et. al., 2019); therefore, a less toxic with a more
therapeutic index drug, AZD0466, was tested in murine lung cancer lines. AZD0466 is a potent
dual BCL2 /BCLXL inhibitor which can drive cells into apoptosis (Patterson et. al., 2021).
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Another drug class is ARV825, which is a BET family protein degrader that provokes senolysis
in senescent cells (Wakita et. al., 2020).
2. Methods and Materials
2.1. Cell lines and drug treatments
The six cell lines were provided by researchers at Virginia Commonwealth University: H Li
(Y856, X577, X381, E889, X911, and Y143). All cell lines were maintained in DMEM (Thermo
Fisher, Waltham, MA, USA) with 10% (v/v) fetal bovine serum (Gemini, West Sacramento, CA,
USA), and 100 U·mL-1 penicillin G sodium/100 μg·mL-1 streptomycin sulfate (Thermo Fisher).
Etoposide (Sigma-Aldrich, St. Louis, MO, USA), ABT263 (AbbVie) ABT199 (APExBio,
Houston TX, USA), A1155463 (APExBio), ARV825 (AbbVie), and AZD0466 (AbbVie) were
all dissolved in DMSO and administered in the dark at the desired concentrations.
2.2 SA-β-galactosidase staining and C12FDG quantification
Histochemical staining of SA-β-galactosidase by X-Gal, quantification of SA-β-galactosidase
positive cells by C12FDG flow cytometry. For X-Gal staining of cells, cells were fixed and
stained. All images taken on an Olympus (Tokyo, Japan) inverted microscope at 20×. For
C12FDG, cells were treated with 100 nM bafilomycin for 60 minutes at 37oC, then 10 μM
C12FDG for 2 hours at 37oC, subsequently, the cells were collected and centrifuged, washed with
PBS and re-centrifuged, finally, the pallet was re-suspended in PBS and immediately analyzed
with flow cytometry (excitation/emission = 490/514).
2.3 Cell viability
Number of viable cells were obtained by hemocytometer at various time points during and/or
after treatment. Media was replenished every 48 hours. Non-viable cells were aspirated and only
viable cells were counted.
2.4. Antibodies
The following primary antibodies were used: cleaved caspase 3 (Cell Signaling, Danvers, MA,
USA. Cat. Num.: 9664S), BCLXL (Cell Signaling. Cat. Num.: 2764S), BCL2 (Abcam,
Cambridge, UK. Cat. Num.: GR249198-74), BCLW (Cell Signaling. Cat. Num.: 2724S) Bax
(Cell Signaling. Cat. Num.: 2772S), Bak (Cell Signaling. Cat. Num.: 12105S), Lamin B1 (Cell
Signaling. Cat. Num.: 12586S), β-actin (Cell Signaling. Cat. Num.: 4976S), Bim (Cell Signaling.
Cat. Num.: 2933S), Cathepsin D (Cell Signaling. Cat. Num.: 2248S), Noxa (Cell Signaling. Cat.
Num.:14766S), P21(Santa Cruz Biotechnology, Santa Cruz, CA, USA. Cat. Num.: SC-397), P53
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(Cell Signaling. Cat. Num.: 9282S). The secondary antibody used was anti-rabbit IgG (Cell
Signaling. Cat. Num.: 7074S).
2.5. Annexin-V/PI and APC Annexin-V/7-AAD apoptosis staining
Apoptosis quantification, based on Annexin-V/PI (BD Biosciences, San Diego, CA, USA) or
APC Annexin-V/7-AAD (BioLegend, San Diego, CA, USA) by flow cytometry were conducted
by collecting supernatant and cells then centrifuge. Wash pallet with PBS and re-centrifuge.
Suspend pellet in 106 μL of staining buffer (per sample: 100 μL 1X Annexin-V Binding Buffer,
3 μL propidium iodide, and 3 μL FITC Annexin-V). Cells expressing GFP were stained with
APC Annexin V (per sample: 100 μL 1X Annexin-V Binding Buffer, 3 μL APC Annexin-V, and
3 μL 7-AAD). Cell were stained for 15 minutes at room temperature and analyzed by flow
cytometry immediately.
2.6. Western blotting
After the indicated treatments, cells were lifted from the culture plates, collected, and lysed using
M-PER mammalian protein extraction reagent (Thermo Scientific, McAllen, TX, USA)
containing protease and phosphatase inhibitors (Sigma Aldrich). Protein concentrations were
determined by the Bradford assay (Bio-Rad Laboratories). Total protein was then diluted in SDS
sample buffer and dry boiled for 5-10 minutes. Protein samples were subjected to SDSpolyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane, and
blocked in 5% FBS, 1x PBS, 0.1% Tween 20 (Fisher) for 2 hours. Primary antibodies used at a
1:1000 dilution except for BCL2 1:2000 dilution and β-actin 1:4000 dilution with overnight
incubation in 4oC, followed by extensive washing with Tween-PBS (PBS with 0.1% Tween 20).
The membrane was then incubated with secondary antibody of horseradish peroxidaseconjugated goat anti-rabbit IgG antibody (1:2000) for 2 hours at room temperature or overnight
in 4oC, followed by extensive washing with Tween-PBS (PBS with 0.1% Tween 20). Blots were
developed using Pierce enhanced chemiluminescence reagents (Thermo Fisher Scientific).
2.7. Statistical analysis
Quantitative data are shown as mean ± SEM from at least three independent experiments, which
were performed in triplicates. For statistical analysis, GraphPad Prism 8 software (San Diego,
CA, USA) was used. Statistical data were analyzed using one- or two-way ANOVA unless
otherwise indicated.
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3. Results
To disclose past research on lung cancer, figures 1, 2, 3 were adapted from studies by Valerie
Carpenter with her permission.
3.1 Senescence induction in A549, a non-small human lung cancer cell line, in vitro.
Cellular senescence is “a well-established, highly-programmed response to various DNA
damaging antitumor modalities wherein a cancer cell enters into a durable and prolonged growth
arrest” (Saleh et al., 2019). ETO, which inhibits topoisomerase II, is used in the treatment of
non-small cell lung cancer. Human non-small-cell lung carcinoma (NSCLC) cells (A549) were
treated with ETO at a concentration of 8.7 μM for 72 hours, based on pharmacokinetic data
(Smyth et. al.). Figure 1A illustrates the promotion of senescence by ETO based on the increased
SA-β-gal activity by X-gal and C12FDG. Another marker of senescence is the degradation of
Lamin B1, which is shown in figure 1B.
A

B

Fig. 1. Etoposide induced senescence in human lung cancer cells, A549. Etoposide A549 cells were
exposed to etoposide at a concentration of 8.7 μM for 72 hours. (A) A549 cells were assessed for
increased expression of SA-β-gal using X-gal (bright-field images, objective 20x) or C12FDG (bar graph).
****P < 0.0001 indicates statistical significance of treated condition compared to controls as determined
using unpaired, Student’s t-test. (B) Western blotting for Lamin B1 following treatment with etoposide.
All images are representative fields or blots from three independent experiments (n = 3), and quantitative
graphs are mean ± SEM from three independent experiments (n = 3).
3.2 A549 Sensitivity to the senolytic, ABT263, in vitro
Cells induced into senescence by ETO were treated with ABT263 and after the treatment of
ABT263, the surviving cells were stained with crystal violet. Figure 2A, shows that treatment
with ABT263 resulted in a significant elimination of senescent cells, but not control cells. Figure
12

2B confirms this finding in a time course study where a single 48-hour treatment with 2 μM
ABT263 notably reduced the number of viable cells, but did not affect the non-senescent cells.
This indicates that ABT263 only targets senescent cells, and has no effect on the non-senescent
cells. It was observed that as ABT263 drives cells toward cell death, its ability to do so,
diminishes over time as the cells recover from senescence, which is observed on days 8 to 14 on
the cell viability time course in the lower portion of figure 2B.
A

B

Fig. 2. A549 sensitivity to senolytic ABT263. (A) Crystal violet assay showing a dose response for
ABT263. A549 cells were treated with vehicle or 8.7 μM ETO for 72 hrs and then exposed to the
indicated concentration of ABT263 for 48 hrs. (B) Cell viability time-courses after treatment of ETO
and/or ETO + ABT263. All images are representative images and line graphs are mean ± SEM from at
three independent experiments (n = 3).

3.3 Senescence induction in the murine lung carcinoma cell line, CMT167
After demonstrating that the A549 human lung cancer cell line, which enters senescence and
responds to the senolytic ABT263, a mouse cell line was essential to study the role of the
immune system in lung cancer with a two-step treatment, senescence induction and the use of
senolytic(s). Seven mouse NSCLC cell lines (CMT167, Y856, X577, X381, E889, Y143, and
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X911) were screened for their β-galactosidase (β-gal) levels by X-gal and C12FDG by flow
cytometry for quantification of senescence. Figure 3 illustrates the experimental timeline for
ETO and ABT263 treatments. To induce senescence, cells were treated on day 0 with 2 μM ETO
for 48 hours and were stained with X-gal or C12FDG for β-gal quantification on day 3.

Fig. 3. Experimental timeline for etoposide and ABT263 treatments. Cells were exposed to ETO for 48
hours, for senescence induction, and were placed in DMEM for 24 hours. Cells were then treated with
ABT263 for 48 hours. All experimental data collected were collected before, during, and after treatment
of ETO and/or ABT263.

Figure 4A presents a dose response for ETO to evaluate the expression of SA-β-gal using X-gal
staining. Senescent cells are enlarged, show an altered morphology and green staining due to the
upregulation of β-galactosidase. An ABT263 concentration of 2 μM was chosen for further
experiments because of the significant increase in staining compared to 0.5 and 1.0 μM, but less
cell death than with 5 μM . Figure 4B presents a time course to evaluate senescence induction by
2 μM of ETO, which peaked at 80% on days 3 and 5. To evaluate the senescent cells response to
the senolytic, ABT263, day 3 was chosen to treat the cells.
A

B

Fig. 4. Etoposide induced senescence in mouse
lung cancer cells, CMT167. (A) Cells were
exposed to ETO, indicated concentrations, for
48 hrs and evaluated on day 3 for their increased
expression of SA-β-gal using X-gal (bright-field
images, objective 20X). (B) SA-β-gal time
course using 2 μM as the choice of
concentration to evaluate the increased
expression of SA-β-gal using X-gal (bright-field
images, objective 20X) or C12FDG for
quantification.
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3.4 CMT167 sensitivity to senolytic, ABT263
In order to eliminate cells induced into senescence, a senolytic was screened to target and drive
them to apoptosis. The cells induced into senescence by ETO were exposed to ABT263 using the
concentrations of 10, 5, 2.5, 1.25, 0.625, 0.3125, and 0 μM (figure 5A) for 48 hours and the
surviving CMT167 cells were stained with crystal violet. ABT263 sensitivity was confirmed by
performing a cell viability time course using 2 μM of ABT 263. Figures 5B illustrates that
ABT263 has no effect on the control cells. As illustrated from the viability time courses (figure
5C) senescent CMT167 cells have a pronounced response to ABT263; however, the effects are
transient and after day 7 of ETO treatment, CMT167 cells recovered from senescence; that is, the
cells continued to grow. Furthermore, the response to the treatment with ABT263 diminished
after day 7 as well. Figure 5C, right panel, when senescent cells escape from senescence, the
treatment of ABT263 will no longer be effective. Fig. 5D illustrates a comparison between ETO
and ETO + ABT. The treatment with ABT263 reduces cell number on day 5 and on day 14. On
day 5, there is a 77.5% reduction in cell viability and on day 14, there is a 23.7% reduction in
cell viability.
To determine whether the ABT263 was promoting apoptosis, cell death was assessed by
Annexin-V/PI staining and FACS analysis; it was observed that ABT263 drives cells toward
apoptosis and there is approximately 50% apoptotic cell death with treatments of ETO followed
by ABT263, figure 5E. Annexin V staining specifies how early and late apoptosis is induced in
every treatment. In all treatments groups, early apoptosis occurs in more cells than late apoptosis,
meaning that the cells were starting the apoptosis process.
3.5. Senescence induction in the syngeneic murine lung cancer cell line, X577
The screening for senescence in the six NSCLC cell lines was chosen on day three because in
previous work with the mouse lung cancer line, CMT167, high levels of senescent positive cells
were detected after day 3 (Fig. 4B). Figure 6A shows that X577 cells undergo senescence in
response to ETO based on the increase of green β-gal staining, cell enlargement and the
granulation of cytoplasmic chromatin fragments (CCFs). Figure 6B, β-gal positive cell
quantification by flow cytometry, indicates that approximately 37% of the cells have entered into
senescence. Figure 6C confirms senescence based on the degradation of Lamin B1. A slight up
regulation of Cathepsin D is another marker of senescence, which is also observed. Also, an
upregulation of p53 and p21 are an indication of senescence because the cells are in a stressful
15

environment due to the treatment of ETO. Since the X577 cells demonstrated senescence
induction, although less than 40%, sensitivity to ABT263 was assessed.
A

B

C

D

E

Fig. 5. CMT167 sensitivity to
ABT263. (A) Crystal violet assay
quantification showing a dose response
to ABT263 with the concentrations of
10, 5, 2.5, 1.25, 0.625, 0.3125, and 0
μM. (B) Cell viability time course for
CMT167 of controls and 2 μM ABT263
only; (C) Cell viability of 2 μM ETO
and/or 2 μM ETO + 2 μM ABT263 and
a close up look of the effect of ABT263
to clarify the response of ABT263. (D)
A bar graph to compare ETO to ETO + ABT treatments on days 5 and 14. ***P ≤ 0.0005 indicates
statistical significance of treated condition compared to their counterpart as determined using unpaired,
Student’s t-test. (E) Annexin-V/PI quantification of apoptosis induced by 2 μM ABT263 with overnight
exposure. Images and line graphs are representative images or graphs from three independent experiments
(n = 3). Bar graph is mean ± SEM.
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A
Controls

B

Senescent

C

D

Fig. 6. Etoposide induced senescence in mouse lung cancer X577 cells. Cells were exposed to ETO (2
μM for 48 hrs) and were evaluated for their increased expression of SA-β-gal using (A) X-gal (brightfield images, objective 20X) or (B) C12FDG, the next day. ** P ≤ 0.0026 indicates statistical significance
of treated condition compared to controls as determined using unpaired, Student’s t-test. (C) Western
blotting of Cathepsin D, Lamin B1, P21, and P53 (D) is a quantification of western blots. All images are
representative images from three independent experiments (n = 3), and quantitative graphs are mean ±
SEM from three independent experiments (n = 3). Western blots and quantifications are one repeat (n =
1).
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3.6. X577 sensitivity to ABT263
Figures 7A and 7B and 7D show that X577 cells induced into senescence by ETO responded to
ABT263 largely in the same manner as the CMT167 cells. Figure 7A and 7B show a dose
response with ABT263 using 5, 2.5, 1.25, 0.625, 0.3125, and 0 μM concentrations. ABT263 has
only a modest effect on the control group; however, when cells are induced into senescence with
the treatment of ETO followed by ABT-263, there is a significant reduction in cell viability.
Figure 7C indicates that control cells treated with ABT263 only show a negligible effect,
indicating that ABT263 doesn’t affect non-senescent cells. In the senescent viability graph
(figure 7D, right panel), it was observed that the treatment with ETO alone induced the cells into
senescence until day 7 and that the cells have recovered by day 10. This recovery indicates that
after the cells have escaped from senescence, ABT263 effects have diminished. Figure 7E is a
comparison of the effects of ETO alone and ETO + ABT263 on days 5 and 10. From cell
viability time courses, ABT263 has more efficacious = on X577 cells than on CMT167.
Again, Annexin-V/PI staining as well as western blotting for caspase 3 cleavage were performed
to investigate the extent of apoptosis shown in figure 8. As expected, senolytic ABT263 exerts
its effects against senescent cells by inducing apoptotic cell death. This is shown by the increase
of Annexin-V/PI staining. With controls, there are about 5% apoptotic cells that appear to be in
late apoptosis. In cells treated with ABT263 only, there appears to be equal levels of early and
late apoptosis that sum up to 7% apoptosis. Cells treated with ETO only, and that have been left
in media for 2 days after treatment, have mostly early apoptosis and when including the late
apoptotic cells, there is a 20% apoptosis. Furthermore, when cells are treated with ETO for 48
hours and were given 24 hours in media and 24 hours with ABT263, there is an increase in
cellular apoptosis and an increase in both late and early apoptosis, indicating that ABT263 drives
the cells to cell death through the apoptotic pathway.
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Fig. 7. X577 sensitivity to senolytic ABT263. (A) Crystal violet assay showing a dose response for
ABT263. (B) Quantification of the crystal violet using ImageJ. (C) Cell viability time courses for X577 of
controls and ABT263 only; (D) Cell viability after treatment of ETO and/or ETO + ABT263 and a close
up look of the effect of ABT263 to clarify the response of ABT263. (E) A bar graph to compare ETO to
ETO + ABT treatments on days 5 and 10. **P ≤ 0.0078 and *P ≤ 0.0186 indicate statistical significance
of treated condition compared to their counterpart as determined using unpaired, Student’s t-test. All
images and line graphs are representative images or graphs from three independent experiments (n = 3).
Bar graph is mean ± SEM from three independent experiments (n = 3).
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A

Fig. 8. ABT263 induces apoptotic cell death in senescent cells
X577. (A) X577 is Annexin-V/PI quantification of apoptosis
induced by 2 μM ABT263 with overnight exposure.
Quantification graph is mean ± SEM from three independent
experiments (n = 3).

3.7. Senescence induction in the syngeneic murine lung cancer cell line, E889
The E889 cell line also shows significance senescent induction with exposure to ETO (figure
9A) with the senescent cells being more granulated and staining for β-gal; β-gal positivity was
approximately 44%. To confirm senescence induction after ETO exposure, Cathepsin D1, p21
and p53 levels were investigated using western blotting (figures 9C and D). Figure 9C illustrates
the accumulation of Cathepsin D. The upregulation of p21 on day 2 was also observed, however,
the protein levels down-regulate on day 3 and 4;, this may indicate that senescence is highest on
day 2. There is also, the accumulation of p53 throughout the treatment with ETO.
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Fig. 9. Etoposide induced senescence in mouse lung cancer E889 cells. Cells were exposed to ETO (2
μM for 48 hrs) and were evaluated for their increased expression of SA-β-gal using (A) X-gal (brightfield images, objective 20X) or (B) C12FDG, the next day. ** P ≤ 0.0023 indicates statistical significance
of treated condition compared to controls as determined using unpaired, Student’s t-test. (C) Western
blotting of Cathepsin D, Lamin B1, P21, and P53 and (D) is western blot quantification. All images are
representative images from three independent experiments (n = 3), and quantitative graphs are mean ±
SEM from three independent experiments (n = 3). Western blots and quantifications are one repeat (n =
1).
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3.8. E889 sensitivity to ABT263
ABT263 reduced the number of E889 senescent cells (Figure 10). Figures 10A and B illustrate
that with the treatment of ABT263 only, the cell viability have to some extent was reduced. After
the induction of senescence by the exposure to ETO, there was a significant reduction in cell
viability after the treatment with ABT263 with 5, 2.5, 1.25, 0.625, 0.3125, and 0 μM doses.
Figures 10C illustrates that E889 cells treated with ABT263 alone showed negligible effects..
Figure 10D shows senescence induction after the treatment with ETO. Cells remain arrested
between days 0 and 5 and by day 7 the cells start to recover. When the cells are treated with ETO
only, there is a reduction in cell viability; this is due to the stress ETO is inducing on the cells.
When senescent cells are treated with ABT263, there is a substantial reduction in the cell
viability; however, the cells escape from senescence, as the effects of ABT263 is diminished.
Figure 10D, right panel, illustrates the recovery of both ETO only and ETO+ABT263 treated
cells. Figure 7E is a comparison of the effects of ETO alone and ETO + ABT263 on days 5 and
12. Numbers were acquired from the same time-course for accuracy. The number of cells are
reduced on day 5 after treatment of ETO+ABT compared to ETO alone. On day 12, cells treated
with ETO+ABT have recovered and have reached the same number of cells as the treatment of
ETO. This indicates that after the recovery of senescence the cells will continue to grow.
In E889 cells, ETO treatment reduces the number of viable cells (fig. 10D). Therefore, it was
tested with lower doses of ETO (0.5 μM and 1 μM ) to observe senescence on days 2, 3, and 5. It
was concluded, from X-gal and C12FDG flow cytometry (supp. figs. 1A, B), the lower doses of
ETO don’t induce senescence as much as 2 μM ETO. And it was decided that the best
concentration of ETO is 2 μM.
To further investigate the effects of ABT263, Annexin-APC/7-AAD staining was performed as
well as western blotting to monitor the levels of cleaved caspase-3 (figure 11). Senolytic
ABT263 exerts its effects against senescent cells by inducing apoptotic cell death. This is shown
by the increase of Annexin-V/PI staining. In figures 11B and C, E889 cells undergo apoptosis
after the ETO treatment (ETO day 2, 3, and 4), and it shows a significant increase in cleaved
caspase 3 after the treatment of both ETO and ABT263. This indicated the increase of apoptosis
with the treatment of ETO+ABT263.
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Fig. 10. E889 sensitivity to senolytic ABT263. (A) Crystal violet assay showing a dose response for
ABT263. (B) Quantification of the crystal violet using ImageJ. (C) Cell viability time courses for Y856 of
controls and ABT263 only; (D) Cell viability after treatment of ETO and/or ETO + ABT263 and a close
up look of the effect of ABT263 to clarify the response of ABT263. (E) A bar graph to compare ETO to
ETO + ABT treatments on days 5 and 12. * P ≤ 0.0206 indicates statistical significance of treated
condition compared to their counterpart as determined using unpaired, Student’s t-test. All images and
line graphs are representative images or graphs from three independent experiments (n = 3). Bar graph is
mean ± SEM from three independent experiments (n = 3).
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Sup. Fig. 1. Lower doses etoposide induced senescence in E889 cells. Cells were exposed to ETO (0.5
or 1 μM for 48 hrs) and were evaluated for their increased expression of SA-β-gal using X-gal (brightfield images, objective 20X) or C12FDG on days 2, 3, and 5. All images are representative images from
three independent experiments (n = 3), and quantitative graph is mean ± SEM from two independent
experiments (n = 2).
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Fig. 11. ABT263 induces apoptotic cell death in senescent cells E889. (A) E889 is Annexin-V/PI
quantification of apoptosis induced by 2 μM ABT263 with overnight exposure. (B) Western blotting for
cleaved caspase 3 for E889. (C) A bar graph quantification of western blot. Quantification graphs are
mean ± SEM from three independent experiments (n = 3) and western blots and quantification is one
repeat (n = 1).
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3.9. Senescence induction in the syngeneic murine lung cancer cell line, X381
The X381 cell line also shows significance senescent induction with exposure to ETO (figure
12A) with the senescent cells being more granulated and staining for β-gal; β-gal positivity was
approximately 55%. Due to its significant level of β-gal staining and the quantification of β-gal,
the effects of ABT263 were investigated with X381 cells.
A

Controls

Senescent

B

Fig. 12. Etoposide induced senescence in mouse lung cancer X381 cells. Cells were exposed to ETO (2
μM for 48 hrs) and were evaluated for their increased expression of SA-β-gal using (A) X-gal (brightfield images, objective 20X) or (B) C12FDG, the next day. *** P ≤ 0.0001 indicates statistical
significance of treated condition compared to controls as determined using unpaired, Student’s t-test. All
images are representative images from three independent experiments (n = 3), and quantitative graphs are
mean ± SEM from three independent experiments (n = 3).

3.10. X381 sensitivity to ABT263
ABT263 reduced the number of X381 senescent cells (Figure 13). Figures 13A and 13B
illustrate that with the treatment of ABT263 alone, the cell viability have to some extent was
reduced. After the induction of senescence by the exposure to ETO, there was a significant
reduction in cell viability after the treatment with ABT263 with 5, 2.5, 1.25, 0.625, and 0.3125
concentrations .
In the control cells, ABT263 slightly slows down the growth, however, the effect is negligible
(figure 13C); in figure 13D, ETO only treated cells were reduced and with the addition of
ABT263 the cell viability number continues to decrease. Figure 13C, right panel, indicates that
the cells recover from senescence between days 7 and 10. ABT263 killed the senescent cells, and
the cells that are left are those that are either resistant to ETO, resistant to ABT263, or both, this
may be the reason why the cells treated with ETO+ABT263 have recovered and have surpassed
the ETO only treated cells. Figure 13E is a comparison of the effects of ETO alone and ETO +
ABT263 on days 5 and 12. Numbers were acquired from the same time-course for accuracy. The
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number of cells are reduced on day 5 after treatment of ETO+ABT compared to ETO alone. On
day 12, cells treated with ETO+ABT have recovered and have surpassed the number of cells
treated with ETO.
B

E
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D

Fig. 13. X381 sensitivity to senolytic ABT263. (A) Crystal violet assay showing a dose response for
ABT263. (B) Quantification of the crystal violet using ImageJ. (C) Cell viability time courses for X381 of
controls and ABT263 only; (D) Cell viability after treatment of ETO and/or ETO + ABT263 and a close
up look of the effect of ABT263 to clarify the response of ABT263. (E) A bar graph to compare ETO to
ETO + ABT treatments on days 5 and 10. **P ≤ 0.0012 indicate statistical significance of treated
condition compared to their counterpart as determined using unpaired, Student’s t-test. All images and
line graphs are representative images or graphs from three independent experiments (n = 3). Bar graph is
mean ± SEM from three independent experiments (n = 3).
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To examine how much cell death in induced by ABT263, an Annexin-APC/7-AAD staining was
assessed (fig. 14), it was observed that there was approximately a 20% increase of cell death with
the treatments of ETO + ABT263. With controls and senescent cells, there is the same amount of
early apoptosis and when cells are treated with ABT253 only or ETO only, there is more late
apoptosis that is observed; furthermore, when the cells are treated with both ETO+ABT263,
there is an increase of late apoptosis.
A

Fig. 14. ABT263 induces apoptotic cell death in
senescent cells X577. (A) X577 is Annexin-V/PI
quantification of apoptosis induced by 2 μM ABT263
with overnight exposure. Quantification graphs are mean
± SEM from three independent experiments (n = 3).

3.11. Senescence induction in syngeneic murine lung cancer cell line, Y143
Figure 15, Y143 doesn’t enter senescence and β-gal quantification (fig. 15B) shows a nonsignificant level of β-gal positive cells. In order to compare these cells with other cell lines that
have significant senescence induction, sensitivity to ABT263 was investigated.
A

Controls

Senescent

B

Fig. 15. Etoposide induced senescence in mouse lung cancer Y143 cells. Cells were exposed to ETO (2
μM for 48 hrs) and were evaluated for their increased expression of SA-β-gal using (A) X-gal (brightfield images, objective 20X) or (B) C12FDG, the next day. ns P ≤ 0.2294 indicates no statistical
significance of treated condition compared to controls as determined using unpaired, Student’s t-test. All
images are representative images from three independent experiments (n = 3), and quantitative graphs are
mean ± SEM from three independent experiments (n = 3).
27

3.12. Y143 sensitivity to ABT263
ABT263 dose responses were obtained (fig. 16). It was concluded from the dose responses that
Y143 doesn’t respond to ETO or ABT263. This indicates that when the cells do not senesce,
ABT263 will have no effect on them.
B

Fig. 16. Y143 sensitivity to senolytic ABT263. (A) Crystal violet assay showing a dose response for
ABT263. (B) Quantification of the crystal violet using ImageJ. All images and line graphs are
representative images or graphs from three independent experiments (n = 3).
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3.13. Senescence induction in the syngeneic murine lung cancer cell line, X911
X911 cells show a significant level of senescence induction, in sup. fig. 2, due to the increase in
β-gal staining. Unfortunately, these cells were detaching from plates and no further investigation
were performed using them.
A

Controls

Senescent

Sup. Fig. 2. Etoposide induced senescence in mouse lung cancer X911 cells. Cells were exposed to ETO
(2 μM for 48 hrs) and were evaluated for their increased expression of SA-β-gal using (A) X-gal (brightfield images, objective 20X) or (B) C12FDG, the next day. **** P < 0.0001 indicates statistical
significance of treated condition compared to controls as determined using unpaired, Student’s t-test. All
images are representative images from three independent experiments (n = 3), and quantitative graphs are
mean ± SEM from three independent experiments (n = 3).

3.14. Summary of observations
Cell lines with significant senescence induction are, from highest senescence induction to lowest:
CMT167, X911, X381, E889, and X577. Y143 cells did not have a significant senescence
induction. Table 1 compares all mouse cell lines. Ordering the cell lines from highest to lowest
sensitivity to ABT263, based on increase in % apoptosis increase from controls on day 4: X577,
E889, CMT167, and X381.
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ETO+AB
TNumber
of cells
(104) at
end-oftreatment
78.25
(D10)
57.75
(D12)
48.00
(D10)
76.00
(D14)
-

%
Reductio
n from
ETO+AB
T to ETO
at end-oftreatment
47.7
(D10)
-4.5
(D12)
0 (D10)
23.7
(D12)
-

24.20

-

ETO Number
of cells
(104) at
end-oftreatme
nt
149.75
(D10)
55.25
(D12)
48.00
(D10)
99.60
(D14)
-

-

-

-

-

-

Cell
line

%
Senescen
ce

ETO Numbe
r of
cells
(104)
on D5

ETO+AB
TNumber
of cells
(104) on
D5

%
Reductio
n from
ETO+AB
T to ETO
on D5

X577

37

14.75

2.5

83.1

E889

44.2

2.7

0.25

90.7

X381

56.9

22

5

77.3

CMT16
7
Y143

80

6

1.35

77.5

17.8

-

-

X911

69

-

-

Increase
in %
Apoptoti
c cells
on D4
56.24
42.00
19.45

-

Table 1. Comparison between cell lines. Senescence induction, number of cells on days 5 and on end of
treatment (day 10/12/14), % reduction was calculated by dividing ETO+ABT by ETO, and increase of %
apoptosis by Annexin on D4 is the % apoptosis of 48 hrs of ETO exposure and 24 hrs of ABT263
exposure compared to controls.

3.15. Etoposide and ABT263 effects on protein levels
In order to understand how the treatments of ETO and/or ABT263 effects the protein levels, to
learn how the proteins induce apoptosis and at what levels of proteins are needed to induce
apoptosis, time-course of western blotting were performed using cell lines X577 and E889.
Figure 17. X577 cells show an up regulation of the BCL2 family anti-apoptotic proteins (BCL2,
BCLXL, and BCLW), particularly BCLXL, after the treatment of ABT263 and/or ETO, this
suggests that these proteins are upregulated due to cellular stress from chemotherapeutic drugs.
Pro-apoptotic proteins (Bak and Bax) are up regulated with the treatments of ETO and/or
ABT263, this denotes the potential activation of cellular apoptosis pathway after senescence
induction and the treatment of ABT263. BH3-only proteins (Noxa and Bim) have also been up
regulated after the treatment of ETO and ABT263, allowing pro-apoptotic proteins to activate the
apoptosis pathway. E889 cells, fig. 18, there is a slight up regulation of the anti-apoptotic
proteins after drug treatment, especially after the induction of senescence. Bak is down regulated
when treated with ABT263 only and when treated with ETO on days 2 and 3, this may imply
that the cells aren’t dying, between days 2 and 3 as much as on day 4 with the treatment of ETO
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alone, and this is also observed in western blotting of cleaved caspase 3, figure 11B and C. On
day 4 of ETO and the combination of ETO and ABT263, there is a down regulation of Bak with
the treatments of ABT or ETO only, it up-regulated on day 4 of ETO only and with the
treatments of ETO + ABT indicating cells may have activated apoptosis. Bax is slightly up
regulated with the treatment of ETO on day 2 and it goes back to its control tone indicating Bax
doesn’t play a role on cellular apoptosis in this cell line, with the up regulation of Bak on day 4
of ETO only and the combination of ETO and ABT263, increases the levels of cellular death due
to the presence of more pro-apoptotic proteins. BH3 proteins, Bim and Noxa, are present in
control cells and cells treated with ABT263 only and ETO only and are slightly up-regulated on
day 4 and as well as with the combination, signifying the promotion of cellular apoptosis.
In conclusion, when cells are treated with ETO they enter intracellular stress and consequently
senescence, which up regulates p53, figures 6C and 9C, this would then up regulate and activate
BH3-only proteins. With the up regulation of BH3-only proteins and the accumulation of proapoptotic proteins along with the inhibition of pro-survival proteins, the cells endure cellular
apoptosis. In conclusion, the changes from western blotting are inconsistent and cannot draw any
definitive conclusion. Figure 22 illustrates the pathway when cells are treated with ETO and/or
ABT263.
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B

Fig. 17. ABT263 selectivity for BCL2 , BCLXL, and BCLW. (A) X577 western blotting for indicated
treatments of BCLXL, BCL2, Bak, Bax, Bim, Noxa, and β-actin. (B) Western blots quantifications
normalized to β-actin using ImageJ. Western blots and quantifications are one repeat (n = 1).
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Fig. 18. ABT263 selectivity for BCL2 and BCLXL. (A) E889 western blotting for indicated treatments of
BCLXL, BCL2, Bak, Bax, Bim, Noxa, and β-actin. (B) Western blots quantifications normalized to β-actin
using ImageJ. Western blots and quantifications are one repeat (n = 1).
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Fig. 22. Etoposide (ETO) and BH3-mimetics pathways. (A) senescence induction by ETO pathway.
CYP3A4/5 metabolizes ETO to the O-demethylated metabolites (catechol and quinone). These
metabolites and the parent drug, ETO, inhibit topoisomerase II causing double stranded DNA breaks and
thus placing the cell in intracellular stress and consequently inducing senescence. (B) Apoptosis
promotion by BH3 mimetic drugs. BH3 mimetics inhibit anti-apoptotic proteins (BCL2, BCLXL, and/or
BCLW) prohibiting them from inhibiting pro-apoptotic proteins (Bak and Bax). From cellular stress and
senescence, p53 is up regulated and activates BH3-only proteins (Bim and Noxa). The pathway was
created using BioRender.com.

3.16. ABT263 specificity between the BCL2 family proteins
BCL2 family members regulate the survival of cells, ABT263 is a BH3 mimetic that inhibits
BCL2 proteins prohibiting them from biding to pro-apoptotic proteins, such as Bak and Bax.
To investigate whether ABT263 exerts its effects by inhibiting BCLXL or BCL2. X577, E889,
and X381 cells were chosen to study the effects of ABT199 or A1155463. A1155463 is a
BCLXL-specific inhibitor and ABT199 is a BCL2-specific inhibitor (Leverson et. al., 2015).
Those three cell lines were chosen because of their senescence induction levels and their
sensitivity to ABT263. After the cells senesced, they were treated with either A1155463 or
ABT199 on day three for 48 hours, following the same time-line as ABT263.
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X577 cells, figure 19A, shows that ABT263 may exerts its effects by targeting BCL XL, however,
it is not clear, and more investigation is needed. E889, figure 19B, clearly shows that ABT263
exerts its effects by targeting BCLXL, because both ABT263 and A1155463 follow the exact
trend of response to the drugs. X381 cells, figure 19C, illustrates that ABT263 induces its effects
by targeting mostly BCLXL, nonetheless, further investigation is needed for certainty.
To further investigate the ABT263 mechanism in cell lines X577 and X381, cells were treated
with first, ETO for 48 hrs, second on day 3, a single treatment of ABT199, the specific BCL 2
inhibitor, with the specific BCLXL inhibitor, A1155463, figure 20. E889 sell line was not chosen
to test this synergic treatment because it was clear that ABT263 induces apoptosis by targeting
BCLXL. It was observed that cells treated with ETO + ABT199 + A1155463, following the same
treatment from ABT263, aren’t affected to the synergic triple drug treatment as ETO + ABT263.
This suggests that ABT263 targets another protein in addition to BCLXL and BCL2, which is
BCLw.
In conclusion, ABT263, has been found to target BCLXL only in E889 cells as well as targeting
BCLXL, BCL2, and/or BCLW in X577 and X381 cells to induce its senolytic effects.
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Fig. 19. ABT263 selectivity between BCL2 or BCLXL in X577, E889, and X381. (A) X577
quantification for crystal violet dose response to ABT199 or A1155463 compared to ABT263.
(B) E889 quantification for crystal violet dose response to ABT199 or A1155463 compared to
ABT263. (C) X381 quantification for crystal violet dose response to ABT199 or A1155463
compared to ABT263. Lines graphs are mean and error ± SEM from three independent
experiments (n = 3).
A

B

Fig. 20. ABT263 selectivity between BCL2 and BCLXL in X577 and X381. (A) X577 quantification for
crystal violet dose response to ETO + ABT199 + A1155463 compared to ETO + ABT263. (B) X381
quantification for crystal violet dose response to ETO + ABT199 + A1155463 compared to ETO +
ABT263. Lines graphs are mean and error ± SEM from three independent experiments (n = 3).
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3.17. ARV825 sensitivity
To broaden the scope of choices to induce cell death in senescent cells, the inhibition of BET
family protein was investigated. To investigate BET inhibitor, ARV825, on murine lung cell
lines Y856, X577, X381, and E889. Non-senescent cells were treated with ARV825 with
different doses of ARV825 for 48 hours (100, 50, 25, 12.5, 6.25 and 0 nM) and were replenished
for another 48 hours using the same doses; and senescent cells were treated with ARV825 the as
the non-senescent were, on day 3 ARV825 was added for 48 hours, with indicated
concentrations, and ARV825 was replenished for another 48 hours using the same doses. From
the crystal violet dose response (figure 21) it was concluded in these cell lines ARV825 does not
induce cellular apoptosis and therefore it cannot be used in these cellular models.
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Fig. 21. Sensitivity to ARV825. (A, B, C, D) Crystal violet assay showing a dose response for ARV825
in lines Y856, X577, X381, and E889, respectively. The highest dose of treatment was 100 nM and the
lowest was 0 nM, we treated with ARV825 for 48 hours and replenished the treatment for another 48
hours. (E, F, G, H) are quantification graphs of dose responses using ImageJ. All images are
representative images from three independent experiments (n = 3) and graphs are mean ± SEM from three
independent (n = 3).
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4. Discussion
The hypothesized approach of a two-step treatment for cancer cells with first a senescence
inducer followed by a senolytic has shown to be a potential treatment for cancer (Robbins, et. al.,
2020). The induction of senescence has proved to be a useful outcome in the treatment of cancer
and for many years the production of senescence induction agents has been encouraged (Nardella
et. al., 2011). Nevertheless, senescent cells have been identified as contributors to tumorigenesis
by promoting many hallmarks of cancer, including evasion of the immune system (Prieto et. al.,
2019). There are other senescence inducers that have been tested in other cellular models like
cisplatin and doxorubicin (Saleh et. al., 2020; Ahmadinejad et. al., 2022). Other senescence inducers

may induce different degrees of senescence which can be a more profound or less profound. This
emphasizes the importance to use senolytics to clear senescent cells.
In this study, it was observed that non-small cell lung cancer cells were induced into senescence
by ETO. The cells were enlarged and were more granulated from the CCFs and demonstrated βgal staining, and up-regulation of p53 and p21. Senescent cells that were treated with ABT263
were driven into apoptosis as shown by plasma membrane structural changes that include the
translocation of phosphatidylserine from the inner to the outer leaflet (extracellular side) of the
plasma membrane, which was analyzed after Annexin V/PI staining.
The hypothesis of this work was different cell lines will have different degrees of senescence and
that the magnitude of the response to senolytics would reflect the extent of senescence induction.
The cell lines that were induced into senescence were, from highest level of senescence to
lowest, CMT167, X911, X381, E889, X577, and Y143. To order the cells lines that respond to
ABT263 from highest percent reduction to lowest on day 5: E889, X577, CMT167, and X381.
To order the same cell lines at the end-of-treatment (end of time-course) based on percent
reduction: X577, CMT167, X381, and E889. Based on the precent apoptosis increase from
controls on day 4 that is induced by the Annexin V staining, cells with the highest percent
apoptosis to lowest, X577, E889, X381, and CMT167. In conclusion, there is no correlation
between the degrees of senescence and the magnitude of the response to senolytic, ABT263.
Cell line

% Senescence positive

% Reduction (D5)

X577

37

83.1

E889

44.2

90.7

X381

56.9

77.3
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One reason behind this lack of correlation between the magnitude of senescence induction and
the response to the senolytic, ABT263, can be the different mutations each cell line has. X577
cell line was derived from a male mouse and has KrasG12D and Smad4+/-. E889 cell line was derived from
a male mouse and has KrasG12D, Map3K7-/-, and GFP+. X381 cell line was derived from a male mouse
and has KrasG12D, PTEN+/-, p53+/-, and GFP+. Y143 cell line was derived from a female mouse and is a
EML4-ALK mutant cell line.

From previous work (Saleh et. al., 2020), ABT263 induced its senolytic effects by targeting
BCLXL, moreover, from work in this project, ABT263 may induce its senolytic effects by
targeting BCLXL in E889 and more than one BCL2 family member in X577 and X381.
One possible approach to improve the response to treatment with ETO and ABT263 would be
for the X577 cells to be re-induced into senescence with the exposure of ETO and re-treated
with ABT263. This may keep the cells in a steady-state of senescence and clear more cells after
the use of the senolytic, which may give a longer remission period. X381 cells stayed in
senescence the longest, compared to the other cell lines tested, and in order to clear more
senescent cells, the cell may need to be treated with multi-treatments of the senolytic, which
would delay the cancer cells’ recovery from senescence when treated with ETO and ABT263.
5. Future directions
Different cell lines respond differently to therapy due to their genetic makeup; furthermore, for
future research, learning how cancer cell lines differ from each other genetically may help
provide guidance as to why they respond differently to therapy. Additionally, why some
senescent cells respond to BCL2 family inhibitors (ABT263) but not BET family protein
degrader (ARV825) ought to be investigated.
One of our goals was to determine how the immune system will interact with NSCLC cells when
treated with a senescence-inducer and a senolytic. In this study, there is one cell line that has
potential use for in vivo studies, X577, using ETO and ABT263 as the drugs of choice. X577
cells respond to ABT263 by up-regulating mostly BCLXL, however, when treated with selective
BCL2 or BCLXL or both, it appeared to have not responded to the senolytics as well as to
ABT263. This may be because ABT263 targets a combination of more than one BCL2 family
protein other than BCL2 and BCLXL only.
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